Recombinant Human Endostatin: Introduction

  • Endostatin is an angiogenesis inhibitor that might interfere with the pro-angiogenic action of growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF/FGF-2). It is a widely researched angiogenesis receptor and has antiangiogenic activity and induces microvascular endothelial cell apoptosis. Endostatin is expressed at high levels in the lungs, kidneys, and liver.
  • Recombinant human endostatin is a recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. It may inhibit proinflammatory cytokines, thereby decreasing hepatic metastasis.

Read Report Overview:

Key Drivers of Global Recombinant Human Endostatin Market

  • The global recombinant human endostatin market is primarily driven by a rise in the number of research & development activities to identify potential applications of recombinant human endostatin, increase in the demand for new breakthrough treatment for cancer and ongoing studies determining potential of the collagen, which promises a breakthrough in the treatment of cancer.
  • Rise in prevalence of cancer is projected to fuel the market. According to the World Health Organization (WHO),  around 18.1 million new cases of cancer were recorded in 2018, with 9.6 million deaths due to the disease
  • Globally, 1 in every 3 people is affected by cancer, with 8.8 million deaths registered in 2015 due to cancer. According to WCRF, 57% of all the cancers (except non-melanoma skin cancer) occur in the less developed countries and 43% in developed countries.

Request a Sample of Recombinant Human Endostatin Market:

Medical Application Segment to Account for Major Share of Global Market

  • In terms of application, the global recombinant human endostatin market can be classified into medical application and scientific application
  • The medical application segment is anticipated to dominate the global recombinant human endostatin market during the forecast period, due to need for new cancer treatment and increase in awareness about use of recombinant human endostatin among healthcare professionals such as physicians and oncologists


Request for Analysis of COVID19 Impact on Recombinant Human Endostatin Market -

North America to Dominate Global Recombinant Human Endostatin Market

  • In terms of region, the global recombinant human endostatin market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global recombinant human endostatin market during the forecast period.
  • The market in North America is anticipated to be driven by an increase in number of prominent pharmaceutical & biotechnology companies evaluating the use of recombinant human endostatin along with current cancer treatment drugs and a rise in expenditure on research based on the use of recombinant technology

Pre-Book Recombinant Human Endostatin Market Report -

Key Players Operating in Global Market

The global recombinant human endostatin market is highly fragmented, with a large number of domestic players accounting for major market share.

More Trending Reports by Transparency Market Research:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.


90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453